Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB4J | ISIN: US82686Q1013 | Ticker-Symbol: XRP2
Frankfurt
01.11.24
08:02 Uhr
15,000 Euro
-0,900
-5,66 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SILENCE THERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
SILENCE THERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
16,00016,60001.11.

Aktuelle News zur SILENCE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.10.Morgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN)11
02.09.Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data3
30.08.H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results1
27.08.Silence Therapeutics plc: Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences192Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision...
► Artikel lesen
16.08.Silence Therapeutics stock holds top pick spot and outperform rating at BMO1
16.08.Analyst Expectations For Silence Therapeutics' Future2
16.08.Silence Therapeutics reports Q2 results2
15.08.Silence Therapeutics plc - 6-K, Report of foreign issuer1
15.08.Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights596Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision...
► Artikel lesen
15.08.Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights158LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing...
► Artikel lesen
27.06.Silence Therapeutics plc - 6-K, Report of foreign issuer1
24.06.Silence Therapeutics Receives $2M Milestone Payment from Hansoh2
24.06.Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma2
24.06.Silence Therapeutics achieves $2M research milestone payment from Hansoh collaboration2
24.06.Silence Therapeutics plc: Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration172Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision...
► Artikel lesen
20.06.The Analyst Landscape: 6 Takes On Silence Therapeutics2
20.06.Silence Therapeutics plc - 6-K, Report of foreign issuer1
20.06.Silence Therapeutics plc: Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)246Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN ("Silence"...
► Artikel lesen
30.05.Silence Therapeutics plc: Silence Therapeutics to Present at Jefferies Global Healthcare Conference260Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision...
► Artikel lesen
17.05.What 7 Analyst Ratings Have To Say About Silence Therapeutics2
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1